PMVP — PMV Pharmaceuticals Income Statement
0.000.00%
Last trade - 00:00- $74.19m
- -$68.09m
- 29
- 51
- 48
- 37
Annual income statement for PMV Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Total Operating Expenses | 34.9 | 58.3 | 77 | 80.1 | 85.4 |
| Operating Profit | -34.9 | -58.3 | -77 | -80.1 | -85.4 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -34.4 | -57.8 | -73.3 | -69 | -74.8 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -34.4 | -57.8 | -73.3 | -69 | -58.7 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -34.4 | -57.8 | -73.3 | -69 | -58.7 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -34.4 | -57.8 | -73.3 | -69 | -58.7 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.769 | -1.28 | -1.61 | -1.44 | -1.14 |